Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ophthotech Corp    OPHT

OPHTHOTECH CORP (OPHT)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/11/2018 06/12/2018 06/13/2018 06/14/2018 06/15/2018 Date
3.23(c) 3.09(c) 3.07(c) 3.02(c) 3.07(c) Last
1 115 490 746 400 312 637 342 937 370 645 Volume
+6.95% -4.33% -0.65% -1.63% +1.66% Change
More quotes
Financials (USD)
Sales 2018 -
EBIT 2018 -61,0 M
Net income 2018 -60,0 M
Debt 2018 -
Yield 2018 -
Sales 2019 -
EBIT 2019 -63,0 M
Net income 2019 -60,0 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0
Capi. / Sales2019 0
Capitalization 111 M
More Financials
Company
Ophthotech Corp. is a biopharmaceutical company,which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases.Its product candidates include Zimura and Gene Therapy.The company was founded by... 
More about the company
Surperformance© ratings of Ophthotech Corp
Trading Rating : - Investor Rating :
More Ratings
Latest news on OPHTHOTECH CORP
06/14OPHTHOTECH : Enters into Gene Therapy Agreements with the University of Florida ..
AQ
06/07OPHTHOTECH : Gains on Gene Pacts with Universities
AQ
06/07OPHTHOTECH CORP. : Entry into a Material Definitive Agreement (form 8-K)
AQ
06/07OPHTHOTECH : Enters into Gene Therapy Agreements with the University of Florida ..
BU
05/29OPHTHOTECH CORP. : Change in Directors or Principal Officers, Submission of Matt..
AQ
05/17OPHTHOTECH : Reports First Quarter 2018 Financial and Operating Results
AQ
05/15OPHTHOTECH : Reports First Quarter 2018 Financial and Operating Results
AQ
05/14OPHTHOTECH CORPORATION (NASDAQ : OPHT) Files An 8-K Departure of Directors or Ce..
AQ
05/14OPHTHOTECH CORP. : Change in Directors or Principal Officers (form 8-K)
AQ
05/10OPHTHOTECH : Completes Patient Recruitment in the Phase 2a Clinical Trial of Zim..
AQ
More news
Sector news : Bio Therapeutic Drugs
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/12GSK says vaccine business president to leave by year-end
RE
06/06Drugmaker Lundbeck to settle U.S. charity probe for $52.6 million
RE
06/01Lilly, Incyte Get FDA OK for Lower-Dose Rheumatoid Arthritis Drug
DJ
05/30Gap in regulating biotech drug copies prompts WHO to step in
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
06/16Chardan Capital Reaffirms Hold Rating for Ophthotech $OPHT  
06/16Pair of “modern day Fagins" that ran a team of shoplifters and sold stolen it..
10
06/15Want the latest upgrades & downgrades for $SNES $VTAE $OPHT $BURL $CNHI? .. 
06/13Ophthotech Corp Receives a Hold from Chardan Capital $OPHT  
06/13-$0.40 EPS Expected for Ophthotech Corp $OPHT This Quarter  
More tweets
Qtime:570
News from SeekingAlpha
06/11YOUR DAILY PHARMA SCOOP : Aduro Biotech Moves Ahead, MannKind Up, Chimerix Dips 
06/07Midday Gainers / Losers (06/07/2018) 
06/07HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (06/07/2018) 
06/07PREMARKET GAINERS AS OF 9 : 05 am (06/07/2018) 
06/07Ophthotech inks gene therapy agreements for RP candidate; shares ahead 13% pr.. 
Chart OPHTHOTECH CORP
Duration : Period :
Ophthotech Corp Technical Analysis Chart | OPHT | US6837451037 | 4-Traders
Technical analysis trends OPHTHOTECH CORP
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 3,25 $
Spread / Average Target 5,9%
EPS Revisions
Managers
NameTitle
Glenn P. Sblendorio President & Chief Executive Officer
David R. Guyer Executive Chairman
Keith Westby Chief Operating Officer & Senior Vice President
David F. Carroll CFO, Treasurer, Principal Accounting Officer & SVP
Axel Bolte Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
OPHTHOTECH CORP-1.60%111
GILEAD SCIENCES-1.97%91 317
VERTEX PHARMACEUTICALS3.44%39 504
REGENERON PHARMACEUTICALS-16.13%33 406
NEUROCRINE BIOSCIENCES, INC.31.87%9 198
GENMAB-6.67%9 197